Metallothionein provides ubiquinone-mediated neuroprotection in Parkinson's disease.
Ebadi
Manuchair
M
Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota, School of Medicine and Health Sciences, P.O. Box 9037, 501 North Columbia Road, Grand Forks, ND 58203, USA. mebadi@medicine.nodak.edu
Sharma
Sushil
S
Muralikrishnan
Dhanasekaran
D
Shavali
Shaik
S
Eken
Josh
J
Sangchot
Patcharee
P
Chetsawang
Banthit
B
Brekke
Leah
L
D000818:Animals; D001921:Brain / Q000187:drug effects; D006801:Humans; D008668:Metallothionein / Q000494:pharmacology*; D008928:Mitochondria / Q000187:drug effects; D019636:Neurodegenerative Diseases / Q000473:pathology / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010085:Oxidative Phosphorylation / Q000187:drug effects; D010300:Parkinson Disease / Q000378:metabolism / Q000473:pathology*; D014451:Ubiquinone / Q000378:metabolism / Q000502:physiology*
D018696:Neuroprotective Agents; D014451:Ubiquinone; D008668:Metallothionein